The effect of niosome preparation methods in encapsulating 5-fluorouracil and real time cell assay against HCT-116 colon cancer cell line

Ugorji, Onyinyechi Lydia; Umeh, Ogochukwu Ngozi Chidimma; Agubata, Chukwuma O.; Adah, Dickson; Obitte, Nicholas C.; Chukwu, A.

doi:10.1016/j.heliyon.2022.e12369

Cited by 14 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the release mechanism reveals the profile of levosulpiride from optimized niosomes gels is linear with the Korsmeyer–Peppas model with a high correlation coefficient (r 2 = 0.9813). The n value of 0.3772 noticed suggests the kinetic pattern is Fickian diffusion, which is often observed with niosomes [ 50 , 51 ].…”

Section: Resultsmentioning

confidence: 97%

Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery

Alnaim

Shah²,

Nair

et al. 2023

Gels

View full text Add to dashboard Cite

Poor aqueous solubility besides extensive hepatic first effect significantly decreases the oral absorption of levosulpiride, which in turn minimizes its therapeutic effectiveness. Niosomes have been extensively investigated as a transdermal vesicular nanocarrier to increase the delivery of low permeable compounds into and across the skin. This research work was to design, develop and optimize levosulpiride-loaded niosomal gel and to evaluate its prospects for transdermal delivery. The Box-Behnken design was used to optimize niosomes by analyzing the impact of three factors (cholesterol; X1, Span 40; X2, and sonication time; X3) on the responses (particle size, Y1, and entrapment efficiency, Y2). Optimized formulation (NC) was incorporated into gel and evaluated for pharmaceutical properties, drug release study, ex vivo permeation, and in vivo absorption. The design experiment data suggest that all three independent variables influence both response variables significantly (p < 0.01). Pharmaceutical characteristics of NC vesicles showed the absence of drug excipient interaction, nanosize (~102.2 nm), narrow distribution (~0.218), adequate zeta potential (−49.9 mV), and spherical shape, which are suitable for transdermal therapy. The levosulpiride release rates varied significantly (p < 0.01) between niosomal gel formulation and control. Greater flux (p < 0.01) was observed with levosulpiride-loaded niosomal gel than with control gel formulation. Indeed, the drug plasma profile of niosomal gel was significantly higher (p < 0.005), with ~3 folds higher Cmax and greater bioavailability (~500% higher; p < 0.0001) than its counterpart. Overall, these findings imply that the use of an optimized niosomal gel formulation can increase the therapeutic efficacy of levosulpiride and may represent a promising alternative to conventional therapy.

show abstract

Section: Resultsmentioning

confidence: 97%

Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery

Alnaim

Shah²,

Nair

et al. 2023

Gels

View full text Add to dashboard Cite

show abstract

“…RTCA works based on the principle of cell adhesion on the gold microelectrodes in the RTCA plate and records the impedance of the electric current flow as a cell index (CI). When HCT-116 cells were seeded in an RTCA plate, cell adhesion and proliferation were observed to impede current flow, and the CI value increased [ 12 , 54 ]. In the presence of 5-FU or 5-FU plus LEU pure drug or proniosomes, decreasing CI over 24 h was observed due to the decreasing proliferation ratio ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Engineering 5-flourouracil and leucovorin-loaded vesicular systems for possible colon specific delivery: In vitro evaluation and real time cell assay against HCT-116 colon cell lines

Ugorji,

Onyishi,

Chukwu

et al. 2024

Heliyon

Self Cite

View full text Add to dashboard Cite

“…To evaluate the efficacy of 5FU-loaded noisome in colon cancer cell lines, Ugorji et al (2022) [171] conducted a real-time cell assay, which is an in vitro cytotoxicity test against HCT-11 colon cancer cell lines. The result showed that compared to the pure drug and empty niosomes, the real-time cell assay indicated that the niosomes loaded with 5-fluorouracil induced more long-lasting cell death.…”

Section: Niosomesmentioning

confidence: 99%

Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives

Adebayo,

Agbaje,

Adesina

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the deadliest malignancies in the US, ranking fourth after lung, prostate, and breast cancers, respectively, in general populations. It continues to be a menace, and the incidence has been projected to more than double by 2035, especially in underdeveloped countries. This review seeks to provide some insights into the disease progression, currently available treatment options and their challenges, and future perspectives. Searches were conducted in the PubMed search engine in the university’s online library. The keywords were “Colorectal Cancer” AND “disease process” OR “disease mechanisms” OR “Current Treatment” OR “Prospects”. Selection criteria were original articles published primarily during the period of 2013 through 2023. Abstracts, books and documents, and reviews/systematic reviews were filtered out. Of over 490 thousand articles returned, only about 800 met preliminary selection criteria, 200 were reviewed in detail, but 191 met final selection criteria. Fifty-one other articles were used due to cross-referencing. Although recently considered a disease of lifestyle, CRC incidence appears to be rising in countries with low, low–medium, and medium social demographic indices. CRC can affect all parts of the colon and rectum but is more fatal with poor disease outcomes when it is right-sided. The disease progression usually takes between 7–10 years and can be asymptomatic, making early detection and diagnosis difficult. The CRC tumor microenvironment is made up of different types of cells interacting with each other to promote the growth and proliferation of the tumor cells. Significant advancement has been made in the treatment of colorectal cancer. Notable approaches include surgery, chemotherapy, radiation therapy, and cryotherapy. Chemotherapy, including 5-fluorouracil, irinotecan, oxaliplatin, and leucovorin, plays a significant role in the management of CRC that has been diagnosed at advanced stages. Two classes of monoclonal antibody therapies have been approved by the FDA for the treatment of colorectal cancer: the vascular endothelial growth factor (VEGF) inhibitor, e.g., bevacizumab (Avastin®), and the epidermal growth factor receptor (EGFR) inhibitor, e.g., cetuximab (Erbitux®) and panitumumab (Verbitix®). However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.

show abstract

The effect of niosome preparation methods in encapsulating 5-fluorouracil and real time cell assay against HCT-116 colon cancer cell line

Cited by 14 publications

References 47 publications

Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery

Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery

Engineering 5-flourouracil and leucovorin-loaded vesicular systems for possible colon specific delivery: In vitro evaluation and real time cell assay against HCT-116 colon cell lines

Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives

Contact Info

Product

Resources

About